Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Terminates Biometrics Services Contract With India’s Siro Clinpharm

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Pfizer has terminated its clinical data management and biometrics services contract with India's Siro Clinpharm as part of its "global strategy to reduce the number of biometric suppliers." Siro Clinpharm is one of the largest and most established players in the Indian clinical research industry

You may also be interested in...

India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?

MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts